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Abstract
Importance—Screening mammography intervals remain under debate in the United States.
Objective—To compare the proportion of breast cancers with less versus more favorable 
prognostic characteristics in women screening annually versus biennially by age, menopausal 
status, and postmenopausal hormone therapy use.
Design—Prospective cohort from 1996-2012.
Setting—Breast Cancer Surveillance Consortium facilities.
Participants—We included 15,440 women aged 40-85 years with breast cancer diagnosed 
within one year of an annual or within two years of a biennial screening mammogram.
Exposure—We updated previous analyses by using narrower intervals for defining annual 
(11-14 months) and biennial (23-26 months) screening.
Main outcomes and measures—We defined less-favorable prognostic characteristics as 
stage IIB or higher, size >15 millimeters, positive nodes, and any one or more of these 
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characteristics. We used log-binomial regression to model the proportion of breast cancers with 
less-favorable characteristics following an annual versus biennial screen by 10-year age groups 
and by menopausal status and current postmenopausal hormone therapy use.
Results—Among premenopausal women, biennial screeners had higher proportions of tumors 
stage IIB+ (relative risk [RR]=1.28, 95% confidence interval [CI]=1.01-1.63, p=0.040), size >15 
mm (RR=1.21, 95% CI=1.07-1.37, p=0.002), and with any less-favorable prognostic characteristic 
(RR=1.11, 95% CI=1.00-1.22, p=0.047) compared with annual screeners. Among women on 
postmenopausal hormone therapy, biennial screeners tended to have tumors with less-favorable 
prognostic characteristics compared to annual screeners; however, CIs were wide and differences 
had only borderline significance. The proportions of tumors with less-favorable prognostic 
characteristics were not significantly larger for biennial versus annual screeners among 
postmenopausal women not on hormone therapy, postmenopausal hormone therapy users after 
subdividing by type of hormone use, or any 10-year age group.
Conclusions and relevance—Premenopausal women diagnosed with breast cancer following 
biennial versus annual screening mammography are more likely to have tumors with less-
favorable prognostic characteristics. Postmenopausal women not using hormone therapy who are 
diagnosed with breast cancer following a biennial or annual screen have similar proportions of 
tumors with less-favorable prognostic characteristics.
Introduction
The frequency at which women should receive screening mammography remains 
controversial in the United States. In 2009, the US Preventive Services Task Force 
(USPSTF) updated their breast cancer screening guidelines to recommend routine biennial 
mammography for women aged 50-74 years, based on modeling evidence suggesting that 
the harms of more frequent screening outweigh the small estimated added benefit of annual 
screening.1,2 In contrast, some organizations such as the American Cancer Society3 and 
other groups4-6 have recommended annual screening starting at age 40 for decades. 
However, during this time, mammography accuracy has improved,7,8 new breast cancer 
treatments have been developed, and interest in tailoring screening recommendations to 
individual risk to maximize the balance of benefits versus harms has increased.9-13
No head-to-head randomized controlled trials (RCTs) have compared annual to biennial 
screening. Thus, recommended screening intervals have mainly been influenced by interval 
cancer rates14 and inferential evidence on tumor growth rates observed in trials.15 Based on 
tumor biology, some have argued that screening intervals should be shorter for younger 
women, whereas less frequent screening may be sufficient for women aged 50 years and 
older.16-19 New RCTs comparing screening mammography intervals with mortality 
endpoints are impractical; thus today, screening interval guidelines must rely on 
observational data20-28 and modeling.2,13,29-31
The Breast Cancer Surveillance Consortium (BCSC) has published several large empirical 
studies comparing the benefits and harms of different screening intervals.20-25 These 
observational data suggest no difference in the proportion of advanced-stage invasive 
cancers with annual compared to biennial screening overall or for women aged 50 and older. 
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These analyses classified all women with two screening mammograms 9-30 months apart 
into annual (median 13 months, range 9-18 months) versus biennial (median 24 months, 
range 19-30 months) screeners. Given the broad ranges used, these prior studies may not 
address subgroups of women who closely adhere to screening guidelines or evaluate 
whether screening at intervals more closely approximating 12 versus 24 months influences 
tumor characteristics in subgroups of women undergoing screening. To more specifically 
determine if annual versus biennial screening is associated with more favorable prognostic 
characteristics in younger or older women, we updated our prior analyses using more recent 
data and narrower definitions for annual (11-14 months) and biennial (23-26 months) 
screening. We evaluated whether proportions of tumors with less-favorable versus more-
favorable prognostic characteristics differed by annual versus biennial screening in 
subgroups of women identified by age, menopausal status, and postmenopausal hormone 
therapy (HT) use.
Methods
Study Setting and Data Sources
We used data from the BCSC (http://breastscreening.cancer.gov).32 BCSC registries collect 
patient and clinical information from community radiology facilities with populations 
similar to the US population.33 Breast cancer diagnoses and tumor characteristics are 
obtained by linking with pathology databases; regional Surveillance, Epidemiology, and End 
Results (SEER) programs; and state tumor registries, with estimated completeness of 
reporting >94.3%.34 BCSC registries and the Statistical Coordinating Center received 
Institutional Review Board approval for active or passive consenting processes or a waiver 
of consent to enroll participants, link and pool data, and perform analysis. All procedures 
were Health Insurance Portability and Accountability Act compliant, and registries and the 
Coordinating Center received a Federal Certificate of Confidentiality and other protections 
for the identities of women, physicians, and facilities.
Participants and Study Design
Women aged 40-85 years were included if diagnosed between 1996 and 2012 with an 
incident invasive breast cancer or ductal carcinoma in situ (DCIS), either as a screen-
detected or interval cancer, and who had at least two screening mammography examinations 
11-14 or 23-26 months apart before diagnosis. The time between the two screening 
examinations was used to classify women as annual (11-14 months) or biennial (23-26 
months) screeners.
We aimed to capture two mechanisms by which breast cancers with less-favorable 
characteristics might result from a longer versus a shorter screening interval: (a) more tumor 
growth between two screening mammograms, leading to more advanced disease at screen 
detection, and (b) more time for a tumor to become symptomatic and clinically detected, and 
therefore more likely to be advanced, after a negative screening mammogram (Figure 1). 
Thus, we included both screen-detected and interval breast cancers diagnosed within one 
year of an annual screening mammogram or two years of a biennial screening mammogram, 
as would be done in the analysis of an RCT. Breast cancers following a positive screening 
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mammogram were considered screen detected and those following a negative screening 
mammogram were considered interval cancers using standard BCSC definitions for 
classifying mammography results.35 Only mammograms that occurred at least one year 
before the end of complete capture of cancers by the BCSC for annual mammograms and at 
least two years for biennial mammograms were included.
Measures and Definitions
Screening mammograms were defined using the indication reported by the radiologist or 
technologist. To minimize misclassification of diagnostic mammography as screening, we 
excluded examinations that were unilateral or were preceded by a mammogram or breast 
ultrasound within nine months.
Women completed a questionnaire at each mammography examination to collect 
information on race and ethnicity, history of first-degree relatives (mother, sister, or 
daughter) with breast cancer, menopausal status, current postmenopausal HT use, and 
history of hysterectomy. If self-reported race/ethnicity was missing, we used information 
from cancer registries. Women were considered postmenopausal if they reported removal of 
both ovaries, periods that stopped naturally or no period for more than 365 days, current HT 
use, or age 55 or older.36 Women were considered premenopausal if they reported currently 
having periods or using oral contraceptives.36 Women were considered to have missing 
menopausal status if they were under 55 years and reported having had a hysterectomy 
without bilateral oophorectomy and were not using HT, or if menopausal status could not be 
determined based on available information. Postmenopausal women were classified by HT 
use. Women using HT with non-missing hysterectomy information (53%) were included in 
subanalysis by HT type. Women with a uterus using HT were classified as using estrogen 
plus progestogen; women without a uterus using HT were classified as using estrogen only, 
based on clinical practice, as previously described.22,37
Four outcomes measured less-favorable prognostic characteristics: American Joint 
Committee on Cancer (AJCC)38 stage IIB or higher; size >15 millimeters; positive nodes; 
and a measure of any one or more of these characteristics. For 262 women missing AJCC 
stage (3% of invasive cancers), stage IIB or higher was imputed based on tumor size or 
extension, nodal status, metastasis, or SEER summary stage, as previously described.22 In 
sensitivity analyses to evaluate our choices for stage and size thresholds, we classified 
tumors as stage IIA or higher and size >20 mm.
Statistical Analysis
We described the participant population by screening interval. We estimated the proportion 
of women with invasive cancer versus DCIS. Among women with invasive cancer, we 
estimated the distribution of tumor characteristics (stage, size, lymph node status) at 
diagnosis by screening interval, and separately by age group and by menopausal status and 
HT use. Among women with invasive breast cancer, we used log-binomial regression39 to 
estimate relative risks (RR) and 95% confidence intervals (CIs) of less-favorable versus 
more-favorable invasive tumor characteristics associated with screening interval by age 
group and by menopausal status and postmenopausal HT use, adjusting for race/ethnicity, 
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first-degree family history of breast cancer, and BCSC registry. In one case for which the 
log-binomial model could not be estimated, we used Poisson regression with robust error 
variances. This approach gave results very similar to log-binomial regression in cases that 
could be estimated using both methods. Based on the observed numbers of women with 
invasive breast cancer, we had 80% power with a two-sided alpha of 0.05 to detect RRs 
within age and menopausal status groups of approximately 1.25-1.35 for stage IIB or higher, 
1.20-1.30 for positive nodes, and 1.10-1.20 for tumors >15 mm and the measure of any one 
or more characteristics. For analyses subdivided by HT type, we had 80% power to detect an 
RR of 1.25-1.55. Analyses were performed in SAS® software, Version 9.2 (SAS Institute, 
Cary, NC).
Results
Among 15,440 women with breast cancer, most were ≥50 years old, white, and 
postmenopausal (Table 1). Biennial screeners were more likely to be in the youngest (40-49 
years) or oldest (70-85 years) age groups and less likely than annual screeners to have a 
family history of breast cancer. Among annual screeners, 77.8% of cancers were screen 
detected compared to 72.8% for biennial screeners.
The proportion of DCIS versus invasive cancers and the proportion of invasive tumors 
associated with less-favorable versus more-favorable prognostic characteristics decreased 
with age (Table 2). For example, 21.3-24.2% of women age 40-49 diagnosed with an 
invasive cancer after a annual or biennial screen were stage IIB or higher, compared to 
16.4% or less among women 60 and older. Within age groups, the proportions of invasive 
tumors versus DCIS were similar among annual versus biennial screeners. Only small and 
inconsistent differences were seen in the proportions of invasive tumors with more-favorable 
versus less-favorable characteristics for annual versus biennial screeners.
Premenopausal women had higher proportions of DCIS versus invasive cancers and invasive 
tumors with less-favorable prognostic characteristics than postmenopausal women (Table 
3). For example, 19.8-25.7% of premenopausal women diagnosed with an invasive cancer 
after a annual or biennial screen were stage IIB or higher compared to 13.2-15.8% of 
postmenopausal women not using HT and 16.1-18.4% of HT users. Within most groups, the 
proportions of invasive tumors versus DCIS were similar among annual versus biennial 
screeners; however, postmenopausal women not using HT had a higher proportion of 
invasive cancers if they were screened biennially compared to annually. Among 
premenopausal women, women screened biennially versus annually had a higher proportion 
of stage IIB or higher tumors (25.7% vs. 19.8%), tumors >15 mm (65.3% vs. 54.6%), and 
node-positive disease (36.6% vs. 31.3%). Differences in these tumor characteristics among 
postmenopausal women were small and inconsistent, regardless of HT use.
We calculated the RRs of less-favorable tumor characteristics for women with invasive 
breast cancer following a biennial versus annual screen, adjusting for race/ethnicity, family 
history of breast cancer, and BCSC registry (Table 4). Within age groups, RR estimates 
were close to one with no significant differences between biennial versus annual screeners. 
However, among premenopausal women, compared to annual screeners, biannual screeners 
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were at increased risk of stage IIB or higher tumors (RR=1.28, 95% CI=1.01-1.63, p=0.040), 
tumors >15 mm (RR=1.21, 95% CI=1.07-1.37, p=0.002), and tumors with any less-
favorable prognostic characteristic (RR=1.11, 95% CI=1.00-1.22, p=0.047). Among 
postmenopausal women not using HT at the time of the mammogram, RR estimates were 
close to one with no significant differences between biennial versus annual screeners except 
for a modest increased risk of tumors >15 mm (RR=1.11, 95% CI=1.00-1.22, p=0.045). 
Among postmenopausal women using HT at the time of the mammogram, RR estimates for 
biennial versus annual screeners were consistently above one, with borderline-significant 
increases in risk of tumors >15 mm (RR=1.13, 95% CI = 0.98-1.31, p=0.087), positive 
lymph nodes (RR=1.18, 95% CI = 0.98-1.42, p=0.089), and tumors with less-favorable 
prognosis (RR=1.12, 95% CI = 1.00-1.25, p=0.053). Subdividing HT users with known 
hysterectomy status by the likely type of HT used did not change most results, which 
remained statistically nonsignificant except for increased risk of tumors >15 mm among 
biennial versus annual screeners using estrogen plus progestogen (RR=1.38, 95% 
CI=1.04-1.82, p=0.024).
Sensitivity analyses that classified tumors as IIA or higher or size > 20 mm did not 
substantially change results (data not shown).
Discussion
Premenopausal women diagnosed with invasive breast cancer following a biennial screening 
mammogram were more likely to have tumors with less-favorable prognostic characteristics 
than women diagnosed following an annual screening mammogram. In contrast, 
postmenopausal women diagnosed with invasive breast cancer after biennial versus annual 
screening showed no statistically significant differences in the likelihood of less-favorable 
prognostic characteristics, with the exception of small differences of borderline significance 
among women taking postmenopausal HT. We found no statistically significant differences 
in breast tumor prognostic characteristics for biennial versus annual screeners within 10-year 
age groups.
Our findings suggest that menopausal status may be more important than age when 
considering breast cancer screening intervals, which is biologically plausible. Tumors 
exposed to estrogen may grow faster, decreasing the detectable preclinical phase and 
resulting in a higher proportion of interval cancers with poorer tumor characteristics.14,15,18 
In addition, breast density decreases after menopause, making it easier to diagnose breast 
cancers when they are smaller.8,40,41 In our sample of premenopausal women with breast 
cancer, 70% were age 40-49 and 30% were age 50-54. In a study of all women in the BCSC, 
only 10% of women aged 40-49 were postmenopausal and 25% of women aged 50-54 were 
premenopausal.36 Thus, if screening guidelines were based on menopausal status rather than 
age, some women between ages 40-54 might be recommended for more frequent screening 
and others, less frequent screening.
Our study refines prior BCSC studies that used wider screening intervals to classify women 
as annual or biennial screeners.20-25 Similar to our study, these prior studies found no 
difference in the proportion of invasive cancers with less favorable prognostic characteristics 
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with biennial versus annual screening for women aged 50 and older.20-22 In contrast to our 
study, White et al. found that women aged 40-49 were less likely to have late versus early 
stage invasive cancer if screened annually compared to biennially;20 however, an updated 
analysis with more recent data that included digital mammography found no difference by 
screening interval in the proportions of late-stage disease for women aged 40-49 years, 
consistent with our findings.21 Kerlikowske et al.22 found a significantly higher proportion 
of less favorable tumors with biennial versus annual screening in women aged 40-49 years 
but only among women with extremely dense breasts; however, CIs were wide within 
density groups. Buist et al. showed the higher interval cancer rates in women aged 40-49 
compared with older women observed in randomized trials were still evident in modern 
(film-screen based) service screening, which they attributed to younger women having 
faster-growing tumors and greater mammographic breast density.18
In other prior BCSC analyses, O'Meara and colleagues25 compared intervals within racial 
and ethnic groups. Biennial versus annual screening was not associated with overall 
increased risk of less-favorable tumor characteristics among women who were white, black, 
or Hispanic and aged 40-49 years, or among Asian women aged 50-74; however, Hispanic 
women aged 50-74 years who were screened biennially versus annually had an increased 
risk of late-stage disease and larger tumors, and Asian women aged 40-49 who were 
screened biennially were at high risk of a node-positive diagnosis. Dittus et al.23 observed 
that premenopausal obese women undergoing biennial screening had a borderline 
significantly increased risk of diagnosis with a tumor >20 mm relative to annual screeners. 
In contrast, across all body mass index categories, postmenopausal women undergoing 
biennial screening versus annual screening did not present with more advanced stage or 
larger tumor sizes. Braithwaite et al.24 examined tumor characteristics among women aged 
66-89 years and found no statistically significant difference in adverse tumor characteristics 
by screening interval within age-by-comorbidity subgroups. Kerlikowske et al.22 found 
women aged 50-74 years undergoing biennial screening mammography had similar risk of 
advanced stage disease as women undergoing annual mammography within subgroups 
defined by HT use and breast density.
These findings add to the body of evidence that is providing greater confidence in the 
potential for advising women and their providers about screening frequency based on 
personal risk factors. When considering recommendations regarding screening intervals, the 
potential benefit of diagnosing cancers at an earlier stage must be weighed against the 
increased potential for harms associated with more frequent screening such as false positive 
recalls and biopsies, which are 1.5 to 2 times higher in annual versus biennial 
screeners.2,21-25,29,30 Future studies should focus on strategies to reduce these harms. We 
also need are studies that improve our understanding of tumor growth rates and 
aggressiveness among pre and postmenopausal women, the duration of the transition from 
shorter to longer sojourn times, and the degree to which risk factors may change the 
association between menopausal status, screening interval, and tumor characteristics 
observed here.
Our study has several limitations. First, the potential for confounding is always a concern in 
observational studies. For example, women who know they have breast cancer risk factors 
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might undergo more frequent screening than women without these factors. We adjusted for 
family history, race, and ethnicity in our analyses to minimize bias, but did not adjust for 
other risk factors such as benign breast disease or reproductive factors. Second, some of our 
comparisons might be significant by chance alone so the magnitude and consistency of 
differences and CI widths should be considered. Another limitation is that we maximized 
sample sizes within subgroups by including data back to 1996, which included film-screen 
mammograms. Overall, the sensitivities of digital and film-screen mammography are 
similar, but sensitivity may be higher for digital mammography in some subgroups, 
especially women with dense breasts and premenopausal women.8,42,43 We did not collect 
HT type, relying instead on a surrogate based on hysterectomy status, which was available 
for only 53% of HT users. Results within HT-type subgroups were inconsistent and had 
wide CIs, limiting our ability to make inferences in this group. Lastly, we did not measure 
breast cancer mortality. Thus, we do not know if the observed increases in the proportions of 
less favorable tumors with biennial versus annual screening would result in differences in 
breast cancer mortality.
Conclusions
Premenopausal women diagnosed with breast cancer following a biennial mammogram are 
more likely to have tumors with less-favorable prognostic characteristics than women with 
breast cancers diagnosed after annual screening. Postmenopausal women not using HT who 
are diagnosed with breast cancer following a biennial or annual screen have similar 
proportions of tumors with less-favorable prognostic characteristics. Results are less clear 
for women using postmenopausal HT. Our findings of a lower proportion of less favorable 
tumors with more frequent screening in premenopausal women, and no statistically 
significant difference in the proportion of less favorable tumors in postmenopausal women 
by screening interval, adds to evidence about the potential benefits and harms of screening 
that policymakers can use to set guidelines about screening intervals and women can use 
when making personal screening decisions with their health care providers.
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Figure 1. Overview of study design
This study captured two mechanisms by which a longer versus shorter screening interval 
might lead to breast cancers with less-favorable characteristics: (1) more time for tumor 
growth between the index screening mammogram m′ and the previous screen m; and (2) 
more time for a tumor to become symptomatic and clinically detected after a negative 
screening mammogram m′. BrCa indicates breast cancer; follow-up, follow-up period for 
cancer ascertainment.
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Table 1
Population Characteristics by Screening Interval for Women With Breast Cancer Who Underwent Screening 




Total number of women 12,070 3,370
Screening interval time, median, months 13 24
Age, %
    40-49 y 13.6 18.2
    50-59 y 29.7 27.4
    60-69 y 29.4 25.3
    70-85 y 27.3 29.1
Race/ethnicity, %
    White, Non-Hispanic 78.4 77.2
    Black, Non-Hispanic 4.5 4.5
    Hispanic 4.5 5.3
    Asian/Pacific Islander 4.9 7.3
    American Indian/Alaska Native 0.4 0.7
    Other or mixed race 1.1 1.4
    Unknown 6.3 3.7
Menopausal Status, %
    Premenopausal 12.6 14.9
    Postmenopausal without hormone therapy use 42.5 40.1
    Postmenopausal with hormone therapy use 21.8 21.0
    Surgical menopausal or unknown 23.1 23.9
Type of postmenopausal hormone therapy use at screen, %
b
    Estrogen + progestogen 46.3 53.8
    Estrogen only 53.7 46.2
First-degree family history of breast cancer, %
    Yes 23.3 18.3
    No 67.4 73.0
    Unknown 9.3 8.8
Type of detection, %
c
    Screen detected (True positive screen) 77.8 72.8
    Interval detected (False negative screen) 22.2 27.2
a
Annual cancers diagnosed within 12 months of screening exam performed 11-14 months after prior mammogram; Biennial cancers diagnosed 
within 24 months of screening exam performed 23-26 months after prior mammogram.
b
Restricted to 1767 women with known hysterectomy status: women with uterus assumed to use estrogen plus progestogen; without uterus 
assumed to use estrogen only.
c
Screen-detected breast cancer diagnosed after a positive screening mammography result and interval breast cancer detected after a negative 
screening mammography result and before the next screening examination.
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Table 2
Distribution of Tumor Characteristics by Age and Screening Interval
Age
40-49 y Screening 
Interval
a
50-59 y Screening 
Interval
a
60-69 y Screening 
Interval
a
70-85 y Screening 
Interval
a
Tumor Characteristic Annual Biennial Annual Biennial Annual Biennial Annual Biennial
No. of breast cancers 
(N=15,440)
1,645 613 3,579 923 3,549 853 3,297 981
    DCIS, % (n=3,340) 26.3 27.4 24.4 22.0 20.7 18.6 18.6 16.0
    Invasive, % (n=12,100) 73.7 72.6 75.6 78.0 79.3 81.4 81.4 84.0
AJCC stage
    No. of invasive cancers 1,137 416 2,460 665 2,542 644 2,429 735
    Stage I, % 54.9 51.0 57.2 56.4 62.3 64.0 68.2 65.7
    Stage IIA, % 23.6 24.3 22.7 24.4 21.0 20.8 17.9 21.6
    Stage IIB, % 12.3 13.2 10.9 9.6 8.9 7.5 7.3 6.4
    Stage III or IV, % 9.2 11.5 9.2 9.6 7.8 7.8 6.6 6.3
AJCC stage IIB or higher
b
    No. of invasive cancers 1,155 425 2,532 680 2,616 666 2,506 782
    Yes, % 21.3 24.2 19.7 19.0 16.4 14.7 13.6 12.1
    No, % 78.7 75.8 80.3 81.0 83.6 85.3 86.4 87.9
Tumor Size
    No. of invasive cancers 1,171 426 2,597 690 2,673 668 2,569 776
    <10 mm, % 23.7 20.2 27.8 23.9 30.6 25.9 33.8 28.2
    10 to <15 mm, % 22.6 17.1 22.9 24.2 24.3 23.8 24.8 26.3
    15 to 20mm, % 23.0 28.6 21.0 24.1 20.4 26.2 20.0 24.2
    >20 mm, % 30.7 34.0 28.2 27.8 24.8 24.1 21.4 21.3
Lymph node
    No. of invasive cancers 1,189 435 2,621 692 2,725 672 2,603 800
    Positive, % 32.5 35.9 28.9 30.5 24.3 22.6 19.2 18.6
    Negative, % 67.5 64.1 71.1 69.5 75.7 77.4 80.8 81.4
Any one or more less-favorable 
characteristic
c
    No. of invasive cancers 1,171 425 2,545 685 2,627 662 2,505 774
    Any, % 59.1 63.1 54.0 53.7 48.6 49.7 44.0 44.6
    None, % 40.9 36.9 46.0 46.3 51.4 50.3 56.0 55.4
Abbreviation: DCIS, ductal carcinoma in situ; AJCC, American Joint Committee on Cancer.
a
Annual includes cancers diagnosed within 12 months of screening exam performed 11-14 months after prior mammogram; Biennial includes 
cancers diagnosed within 24 months of screening exam performed 23-26 months after prior mammogram.
b
AJCC stage IIB or higher was imputed based on tumor size or extension, nodal status, metastasis, or SEER summary stage, when available, for 
women missing AJCC stage.
c
Stage IIB or higher, tumor size >15 mm, or positive nodes.
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Table 4
Relative Risk (95% confidence interval) of Less-favorable Invasive Cancer Characteristics for Biennial versus 
Annual Screeners, by Age, Menopausal Status, and Current Hormone Therapy Use, Adjusted for Race/
Ethnicity, First-Degree Family History of Breast Cancer, and Breast Cancer Surveillance Consortium Registry 
Using Log-Binomial Regression Unless Otherwise Specified
Tumor Prognostic Characteristic
Stage IIB, III, or IV vs. 
I or IIA
a
Tumor size >15 mm 
vs. <=15 mm
a







    40-49 y 1.17 (0.93, 1.46) 1.10 (0.98, 1.25) 1.09 (0.92, 1.29) 1.04 (0.94, 1.14)
    50-59 y 0.98 (0.80, 1.21) 1.09 (0.97, 1.21) 1.05 (0.90, 1.22) 1.03 (0.94, 1.12)
    60-69 y 0.99 (0.79, 1.24) 1.13 (1.00, 1.27) 0.93 (0.78, 1.12) 1.07 (0.97, 1.19)
    70-85 y 0.98 (0.76, 1.27) 1.13 (0.99, 1.29) 0.91 (0.74, 1.12) 1.05 (0.94, 1.18)
Menopausal status
    Premenopausal 1.28 (1.01, 1.63) 1.21 (1.07, 1.37) 1.15 (0.96, 1.38) 1.11 (1.00, 1.22)
    Postmenopausal, without HT 
use
0.95 (0.79, 1.15) 1.11 (1.00, 1.22) 0.89 (0.77, 1.04) 1.03 (0.95, 1.12)
    Postmenopausal, with HT use 1.14 (0.89, 1.47) 1.13 (0.98, 1.31) 1.18 (0.98, 1.42) 1.12 (1.00, 1.25)
        Estrogen plus progestogen 
used
c 1.01 (0.94, 1.08)
d 1.38 (1.04, 1.82) 0.95 (0.64, 1.41) 1.16 (0.91, 1.47)
        Estrogen only used
c 1.19 (0.78, 1.83) 1.19 (0.95, 1.50) 1.26 (0.90, 1.77) 1.14 (0.94, 1.37)
Abbreviation: HT, postmenopausal hormone therapy.
a
Bold, significantly different from one.
b
Less favorable = stage IIB or higher, size >15 mm, or node positive.
c
Analysis restricted to women with known hysterectomy status: with uterus assumed to be estrogen plus progestogen; without uterus assumed to be 
estrogen only.
d
Relative risk estimated by Poisson regression with robust error variance.
JAMA Oncol. Author manuscript; available in PMC 2016 November 01.
